Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3203878 | 0.95 | MAPT (0.90) | MAPTALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL3147292 | 0.94 | MAPT (0.88) | MAPTALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL10035910 | 0.89 | MAPT (0.80) | MAPTALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL10036432 | 0.89 | MAPT (0.80) | MAPTALDH1A1LMNASMN1; SMN2GPR119 | |
| SCHEMBL23783084 | 0.88 | MAPT (0.78) | MAPTALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL30722421 | 0.88 | MAPT (0.78) | MAPTALDH1A1LMNASMN1; SMN2GPR119 | |
| SCHEMBL8352689 | 0.88 | MAPT (0.78) | MAPTALDH1A1LMNASMN1; SMN2GPR119 | |
| SCHEMBL5573222 | 0.87 | MAPT (0.76) | MAPTALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL25845748 | 0.87 | MAPT (0.76) | MAPTALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL29986023 | 0.87 | MAPT (0.76) | MAPTALDH1A1LMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066389-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
| US-12139492-B2 | Substituted pyrimidines for the targeted degradation of Bruton's tyrosine kinase | ENDOTARGET INC. | 2024-11-12 | — | — | US | disclosed |
| US-20240360146-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-10-31 | — | — | US | disclosed |
| EP-4433457-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | Rgenta Therapeutics, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| EP-4428130-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-09-11 | — | — | EP | disclosed |
| US-20240269298-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-08-15 | — | — | US | disclosed |
| CN-118271284-A | Estrogen receptor modulators and uses thereof | 江苏威凯尔医药科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118159532-A | Compound with BTK protein degradation activity and medical application thereof | 尤比克斯治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024117789-A1 | PLK1 DEGRADATION INDUCING COMPOUNDS WITH INCREASED RIGIDITY | UPPTHERA, INC. (KR) | 2024-06-06 | — | — | WO | disclosed |
| WO-1999021845-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
| EP-0885213-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1999004796-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-04 | — | — | WO | disclosed |
| EP-0892783-A1 | CARBOXYLIC ACID DERIVATIVES WITH AN AGGREGATION-INHIBITING ACTION | Dr. Karl Thomae GmbH (DE) | 1999-01-27 | — | — | EP | disclosed |
| EP-0885213-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-12-23 | — | — | EP | disclosed |
| WO-1998035956-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS OXIDO-SQUALENE CYCLASE INHIBITORS | ZENECA LIMITED (US) | 1998-08-20 | — | — | WO | disclosed |
| WO-1998025617-A1 | SUBSTITUTED ARYL PIPERAZINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| WO-1997037975-A1 | CARBOXYLIC ACID DERIVATIVES WITH AN AGGREGATION-INHIBITING ACTION | DR. KARL THOMAE GMBH (DE) | 1997-10-16 | — | — | WO | disclosed |
| WO-1997025323-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | disclosed |
| US-5556969-A | Benzodiazepine derivatives | MERCK SHARP & DOHME LTD. (GB) | 1996-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269298-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | EGFR, BLK, CSNK1A1L | MAPT 2478/4885ALDH1A1 4631/4885LMNA 1804/4885 |
| US-12139492-B2 | Substituted pyrimidines for the targeted degradation of Bruton's tyrosine kinase | BTK, BCL6B, BCL9 | MAPT 4237/4885ALDH1A1 3275/4885LMNA 4052/4885 |
| US-20250066389-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | SNRPA, SF3B5, RBM17 | MAPT 3969/4885ALDH1A1 1405/4885LMNA 346/4885 |
| US-20240360146-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | BTK, ZAP70, SYK | MAPT 4559/4885ALDH1A1 4835/4885LMNA 2845/4885 |
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | BTK, LYN, SYK | MAPT 3790/4885ALDH1A1 4704/4885LMNA 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.